If an HIV prevention pill that provides a month of protection at a time performs well in two ongoing clinical trials, it could become the next big thing in HIV prevention after the lenacapavir injection. A new licensing agreement is paving the way for South Africa’s Aspen Pharmacare to produce the pill should the study findings be positive and the drug be registered.
Eight months after the Supreme Court of Appeal gave the green light for specially trained pharmacists to dispense antiretrovirals without a script from a doctor, the programme remains stuck in the starting blocks. With enabling permits now seemingly on the horizon, Angela Tembo and Dr Deanne Johnston ask if there has been sufficient planning to make the initiative a success.
As South Africa marks 50 years since the June 1976 youth uprising for a dream of freedom, a new generation of young people dreaming of an HIV-free future gave their time, trust, and participation to help deliver a breakthrough new HIV prevention product that was launched this June, writes Ntando Yola.
A Supreme Court of Appeal ruling in October 2025 cleared the way for specially trained and permitted pharmacists to dispense antiretroviral medicines without a doctor’s script. Seven months later, no pharmacists are yet providing these services. Catherine Tomlinson explores the reasons for the delay.
From the first reported cases of HIV in 1981 to the latest breakthroughs in long-acting prevention, this Spotlight timeline traces key moments in the global and South African response to the virus. It highlights scientific milestones, political controversies, activism, and the human stories that shaped one of the most significant public health challenges of our time.
In South Africa, many mothers and their babies have to visit the clinic more than 10 times in the first six months of the postnatal period. Early findings from an ongoing implementation science project suggests we can get this down to five. The hope is that the new approach will also help reduce HIV transmission from mothers to their babies. Elri Voigt reports.
Spotlight has launched a new HIV dashboard and graph generator based on outputs from the Thembisa model. Our hope is that this dashboard will help the public and people working in healthcare to find important HIV numbers more easily. Please take a look and let us know what you think of it.
An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.
South Africa is staging a sequel to Mbeki-era denialism, only this time, the science, solutions, and costs are clearer, argues Professor Francois Venter.
We’re watching the largest HIV treatment programme in the world unravelling in real time. We don’t need perfection, but we do need a combination of urgency, action, and strategy to save it, argues Professor Francois Venter.
Elzette Rousseau from the Desmond Tutu HIV Foundation told attendees at the top HIV conference in The United States about a project taking HIV prevention services to schools in Cape Town. Biénne Huisman visited one of the sites to find out how it works.
After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
